Skip to content
Try Mental Wellness – Lifestyle
Author:
Haisco Pharmaceutical Group Co., Ltd.
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
August 25, 2026
Haisco’s Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH
July 23, 2026
Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications
June 23, 2026
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas
June 1, 2026